Results 1 to 10 of about 15,721 (211)
Overexpressed pseudogene MT1L associated with tumor immune infiltrates and indicates a worse prognosis in BLCA [PDF]
World Journal of Surgical Oncology, 2021 Background BLCA is a common cancer worldwide, and it is both aggressive and fatal. Immunotherapy (ICT) has achieved an excellent curative effect in BLCA; however, only some BLCA patients can benefit from ICT.
Mengge Chen, Gaili Chen, Yahua Zhong
exaly +5 more sources
Exploration of neutrophil-associated genes in the prognosis of bladder urothelial carcinoma based on a machine learning and multi-omics data integration framework [PDF]
Human GenomicsBackground Bladder urothelial carcinoma (BLCA) is a prevalent malignancy. The poor performance of existing therapeutic approaches in the advanced stages of BLCA underscores the critical need for more sensitive and precise biomarkers to improve patient ...
Muya Ran +7 more
doaj +2 more sources
Cancer & Metabolism, 2023 Background Bladder cancer (BLCA) research in Koreans is still lacking, especially in focusing on the prediction of BLCA. The current study aimed to discover metabolic signatures related to BLCA onset and confirm its potential as a biomarker.
Youngmin Han +7 more
doaj +1 more source
BMC Cancer, 2022 Background Pituitary tumor transforming gene-1 (PTTG1) transcription factor is identified as carcinogenic and associated with tumor invasiveness, but its role in bladder cancer (BLCA) remains obscure.
Jian-Di Li +10 more
doaj +1 more source
BMC Cancer, 2022 Background Bladder cancer (BLCA) is one of the most common genitourinary malignancies in the world, but its pathogenic genes have not been fully identified and the treatment outcomes are still unsatisfactory. Although the members of 2', 5'-oligoadenylate
Lijuan Gao +11 more
doaj +1 more source
Cell Division, 2023 Background Nucleosome-localized sirtuin 4 (SIRT4) was found to function as an oncogene and tumor suppressor gene in different tumors. However, the clinical significance of SIRT4 in bladder urothelial carcinoma (BLCA) has not been assessed, nor has the ...
Jie Yin +5 more
doaj +1 more source
AIM2 inflammasome activation benefits the therapeutic effect of BCG in bladder carcinoma
Frontiers in Pharmacology, 2022 A large proportion of bladder cancer (BLCA) patients suffer from malignant progression to life-threatening muscle-invasive bladder cancer (MIBC). Inflammation is a critical event in cancer development, but little is known about the role of inflammation ...
Houhong Zhou +10 more
doaj +1 more source
Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway
Cancer Cell International, 2022 Background Bladder cancer (BLCA) is one of the most common malignancies worldwide. One of the main reasons for the unsatisfactory management of BLCA is the complex molecular biological mechanism.
Piao Li +10 more
doaj +1 more source
NUPR1 imparts oncogenic potential in bladder cancer
Cancer Medicine, 2023 Background NUPR1, or p8, is a small chromatin protein that plays a central role in the resistance to treatment and progression of cancer. Nevertheless, the molecular mechanism of NUPR1 in bladder cancer (BLCA) remains unclear.
Lifeng Zhang +7 more
doaj +1 more source
Biomolecules, 2022 The purpose of this study was to explore the relationship between bladder urothelial cancer (BLCA) and immunity, to screen prognosis-related immune genes (PIGs), and to construct an immune-related prognosis model (IRPM). We processed the relevant data of
Jiange Zhang +8 more
doaj +1 more source